{
  "abstract": "Background and Importance Severe asthma (SA) is a heterogeneous disease characterised by different inflammatory phenotypes that influence treatment response. Tezepelumab, has shown efficacy across phenotypes, but real-world data comparing its effectiveness by phenotype is still limited. Evaluating this variability is essential to optimise personalised therapy and clinical outcomes.Aim and Objectives To evaluate the effectiveness of tezepelumab in patients with SA based on the asthma phenotype.Material and Methods Retrospective, observational study (October -2023 to September-2025) in patients with AS treated with tezepelumab. Variables: age, sex, asthma phenotype, forced expiratory volume in one second (FEV1), fractional exhaled nitric oxide (FENO), Asthma Control Test (ACT) score; dyspnoea (mMRC scale), number of glucocorticoid cycles (GC), number of emergency visits/hospitalisations (EH). Clinical effectiveness based on asthma phenotype was measured by comparing data at baseline and 10 months of treatment. Statistical analysis was performed in R software using Student’s t-test. P <0.05 was considered statistical significance.Results Thirty-four patients with SA treated with tezepelumab were included; 81.2% women, 52 years (sd: 15), 66.7% allergic-phenotype (AP), and 33.3% eosinophilic-phenotype (EP).In AP, mean baseline: FEV1: 74.9% (sd: 28.0), FENO 42.9 ppb (sd: 49.8); ACT 11 (sd: 5). At 10 months: FEV1: 88.5% (sd: 17.8), FENO 30.5 ppb (sd: 30.3); ACT 17 (sd: 6).In EP, mean baseline: FEV1 75.6% (sd: 20.8), FENO 30.2 ppb (sd: 26.1); ACT 11 (sd: 4). At 10 months: FEV1 81.4% (sd: 17.1%), FENO 22.3 ppb (sd: 18.5); ACT 13 (sd: 5).During treatment, GC decreased from 3.6 to 0.6 in AP and from 5.6 to 3.6 in EP. Dyspnoea improved one point on the mMRC scale in both groups, from II to I in AP and from III to II in eosinophilics. EH decreased by 80.1% in allergics and 75.0% in eosinophilics.Comparing both phenotypes, statistically significant differences were observed in FENO with a mean reduction of 19.8 ppb greater in the EP (p=0.008) and a mean increase of 4.5 points more in the ACT in AP vs. EP (p=0.033).Conclusion and Relevance Tezepelumab improved lung function, asthma control, and decreased the GC and emergencies/hospitalisations in both phenotypes. However, greater improvements in asthma control in AP and the airway inflammation in EP were observed.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Hospitalary Complex of Jaén, Pharmacy Department, Jaén, Spain"
      ],
      "name": "B Morales Rivero"
    },
    {
      "affiliations": [
        "Hospitalary Complex of Jaén, Pharmacy Department, Jaén, Spain"
      ],
      "name": "A Plaza Arbeo"
    },
    {
      "affiliations": [
        "Hospitalary Complex of Jaén, Pharmacy Department, Jaén, Spain"
      ],
      "name": "A Abenza Guardiola"
    },
    {
      "affiliations": [
        "Hospitalary Complex of Jaén, Pharmacy Department, Jaén, Spain"
      ],
      "name": "MJ Barbero Hernandez"
    }
  ],
  "title": "4CPS-258 Effectiveness of tezepelumab in the treatment of severe asthma in allergic and eosinophilic phenotypes",
  "uid": "7dbdb541-45cb-5fca-a265-37a49435e765"
}